文献速递心力衰竭与心肌病

儿童期起病严重心肌病的遗传基础

Genetic Basis of Severe Childhood-Onset Cardiomyopathies.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

研究基于芬兰全国66例严重儿童心肌病队列(KidCMP),采用二代测序及遗传、细胞生物学和计算验证,39%患者检出致病变异,其中46%为新发、34%为隐性、20%为显性遗传。结论认为儿童心肌病多由罕见家庭特异性突变引起,新发突变最常见, trio 二代测序是首选诊断方法,遗传诊断可指导干预和预后判断。

要点

  • 39%的严重儿童心肌病患者可检出致病变异,新发突变占46%。
  • 遗传诊断可提示治疗方向并预测预后,如CALM1与致命性心律失常、TAZ与良好心脏预后相关。
  • trio 二代测序是儿童心肌病遗传诊断的首选方法。

核心结论

  • 儿童心肌病通常由罕见家庭特异性突变引起,新发突变最常见, trio 二代测序是首选诊断方法。
  • 遗传诊断可提示干预策略并预测预后,有助于优先安排心脏移植或保守治疗。

研究设计与样本

  • 研究收集芬兰唯一心脏移植中心的国家级严重儿童心肌病队列KidCMP,共66例。
  • 采用二代测序进行遗传诊断,并利用遗传、细胞生物学和计算方法验证。

主要发现

  • 队列中位诊断年龄为0.33年,17例患者接受心脏移植。
  • 39%患者检出致病变异,其中46%为新发、34%为隐性、20%为显性遗传。
  • 报道NRAP为儿童扩张型心肌病的致病基因,并发现已知心脏病基因的新表型。
  • CALM1与致命性心律失常相关,TAZ与良好心脏预后相关,具有即时治疗意义。
  • 疾病基因集中于代谢、MAPK通路、发育、钙信号和肌节收缩周期等通路。

临床怎么用

  • 对严重儿童心肌病患者应优先采用 trio 二代测序进行遗传诊断。
  • 遗传诊断结果可用于指导干预策略和预后判断,并辅助心脏移植与保守治疗的决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Childhood cardiomyopathies are progressive and often lethal disorders, forming the most common cause of heart failure in children. Despite severe outcomes, their genetic background is still poorly characterized. OBJECTIVES: The purpose of this study was to characterize the genetics of severe childhood cardiomyopathies in a countrywide cohort. METHODS: The authors collected a countrywide cohort, KidCMP, of 66 severe childhood cardiomyopathies from the sole center in Finland performing cardiac transplantation. For genetic diagnosis, next-generation sequencing and subsequent validation using genetic, cell biology, and computational approaches were used. RESULTS: The KidCMP cohort presents remarkable early-onset and severe disorders: the median age of diagnosis was 0.33 years, and 17 patients underwent cardiac transplantation. The authors identified the pathogenic variants in 39% of patients: 46% de novo, 34% recessive, and 20% dominantly-inherited. The authors report NRAP underlying childhood dilated cardiomyopathy, as well as novel phenotypes for known heart disease genes. Some genetic diagnoses have immediate implications for treatment: CALM1 with life-threatening arrhythmias, and TAZ with good cardiac prognosis. The disease genes converge on metabolic causes (PRKAG2, MRPL44, AARS2, HADHB, DNAJC19, PPA2, TAZ, BAG3), MAPK pathways (HRAS, PTPN11, RAF1, TAB2), development (NEK8 and TBX20), calcium signaling (JPH2, CALM1, CACNA1C), and the sarcomeric contraction cycle (TNNC1, TNNI3, ACTC1, MYH7, NRAP). CONCLUSIONS: Childhood cardiomyopathies are typically caused by rare, family-specific mutations, most commonly de novo, indicating that next-generation sequencing of trios is the approach of choice in their diagnosis. Genetic diagnoses may suggest intervention strategies and predict prognosis, offering valuable tools for prioritization of patients for transplantation versus conservative treatment.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Vasilescu C, Ojala TH, Brilhante V, et al. Genetic Basis of Severe Childhood-Onset Cardiomyopathies. J Am Coll Cardiol. 2018. PMID: 30384889. doi:10.1016/j.jacc.2018.08.2171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。